Image source: Getty Images.
Since the day MannKind‘s (NASDAQ: MNKD) inhaled-insulin device Afrezza earned FDA approval just over two years ago, the company’s stock has lost about 92.6% of its value. Now that MannKind’s former marketing partner Sanofi has returned rights to commercialize Afrezza to the embattled company, a successful relaunch of the device is critical.